Michael Henry on Muck Rack

Michael Henry

Marlton
As seen in: American Journal of Public Health Podcast, Nature, Wiley Online Library, Frontiers, MDPI, Medscape, BiggerPockets, American Journal of Public Health, Psychiatric Times, American Journal of Physiology and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Michael

Contact Michael, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Large-Scale Collaborative Assessment of Binding Free Energy Calculations for Drug Discovery Using OpenFE Click to copy article link Article link copied!

|
By Hannah M. Baumann, Joshua Horton, Michael Henry
| dx.doi.org
Open in Who Shared Issue with article?

Question for experienced RE agents

|
By Ben Biggs Verified, Brett Synicky, Russell Brazil, Michael Henry
| BiggerPockets Verified
Hello Everyone, I'm new in town and Just getting started in Real Estate. I'm about to take the RE exam and I'm mentoring full time with a broker. I'm hot on tapping my own personal network about my upcoming career and I'm asking everyone I know for referrals. This question is meant for experienced agents (5+ years) but anyone is invited to join. What is the ONE thing you suggest a new agent focus on with all their might starting out?
Open in Who Shared Issue with article?

Blinatumomab consolidation in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia: final 5-year follow-up analysis of a randomized multicenter phase 3 study | Leukemia

|
By Franco Locatelli, Carmelo Rizzari, Bernd Gruhn, Arnaud Petit, Cornelia Eckert, Anja Möricke, Christina Peters, Vaskar Saha, Michael Henry, Gerhard Zugmaier
| Nature Verified
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the standard of care consolidation treatment in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL) who achieve a second complete remission with conventional chemotherapeutic regimens [1, 2]. Blinatumomab—a CD3/CD19-directed bispecific T-cell engager (BiTE®) molecule—was shown to confer superior event-free survival (EFS) versus chemotherapy in children with high-risk first-relapse B-ALL [3].
Open in Who Shared Issue with article?
See all 30 licensed articles (39 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified